RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor

Area of Science:

• Medicinal Chemistry
• Photodynamic Therapy
• Oncology

Background:

• Cutaneous T-cell lymphomas (CTCL) are a group of cancers affecting the skin.
• Ruxolitinib is a Janus kinase (JAK) inhibitor used in CTCL treatment.
• Targeted drug delivery and light-activated therapies offer potential for improved treatment outcomes.

Purpose of the Study:

• To synthesize and evaluate ruthenium-bipyridine ruxolitinib (RuBiRuxo) as a photoreleasable JAK inhibitor.
• To assess the efficacy of RuBiRuxo in inhibiting CTCL cell proliferation and inducing apoptosis upon light activation.
• To investigate the mechanism of action, including the effect on STAT protein phosphorylation.

Main Methods:

• Synthesis of the novel ruthenium-bipyridine ruxolitinib (RuBiRuxo) compound.
• Assessment of RuBiRuxo stability and photorelease kinetics under visible light.
• In vitro biological testing on a CTCL cell line, including cell proliferation assays and apoptosis detection.
• Analysis of STAT protein phosphorylation levels post-treatment.

Main Results:

• RuBiRuxo was efficiently synthesized and demonstrated stability in aqueous solution.
• Visible light rapidly photoreleased ruxolitinib from the RuBiRuxo compound.
• Irradiation of RuBiRuxo significantly reduced CTCL cell proliferation and induced apoptosis in a light- and time-dependent manner.
• The observed anti-cancer effects were specific and mediated by decreased phosphorylation of STAT proteins.

Conclusions:

• Ruthenium-based photocompounds like RuBiRuxo represent a promising new class of drugs for photodynamic therapy.
• Light-activated RuBiRuxo offers a targeted approach for treating cutaneous lymphomas.
• This study highlights the potential of photopharmacology in developing novel therapeutic strategies for various pathologies.